2003
DOI: 10.1016/s0140-6736(03)12110-1
|View full text |Cite
|
Sign up to set email alerts
|

Autologous bone-marrow stem-cell transplantation for myocardial regeneration

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

7
674
1
54

Year Published

2005
2005
2015
2015

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 1,237 publications
(736 citation statements)
references
References 5 publications
7
674
1
54
Order By: Relevance
“…Unlike MSC, MAPC can be cultured indefinitely in a relatively nutrient-poor medium. MAPC exhibit many of the features and capabilities of embryonic stem cells [14][15][16][17][18][19][20][21][22][23][24].…”
Section: Multipotent Adult Progenitor Cellsmentioning
confidence: 99%
See 1 more Smart Citation
“…Unlike MSC, MAPC can be cultured indefinitely in a relatively nutrient-poor medium. MAPC exhibit many of the features and capabilities of embryonic stem cells [14][15][16][17][18][19][20][21][22][23][24].…”
Section: Multipotent Adult Progenitor Cellsmentioning
confidence: 99%
“…In patients in whom autologous bone marrow cells were injected directly into the damaged myocardium, some improvement in cardiac function was documented based on medication use, quality of life and MRI studies [17]. In a separate study, after autologous AC 133+ bone marrow cells were injected into infarction borders following coronary artery bypass grafting (CABG), improved perfusion and cardiac function may have occurred [18][19][20][21][22][23][24][25][26][27][28][29][30].…”
Section: Demonstration Of Bone Marrow Plasticitymentioning
confidence: 99%
“…MNC preparations contain mainly different stages of progenitor cells and true HSCs and MSCs are rare in these autografts. Smaller studies established the safety of this approach and demonstrated functional and metabolic regeneration of myocardial tissue (Strauer et al, 2005), improvement of vascular function (Erbs et al, 2005), global left ventricular performance (Stamm et al, 2003;Fernandez-Aviles et al, 2004), and peripheral vascular disease (TateishiYuyama et al, 2002). Based on these promising results, larger randomized multicenter trials were conducted.…”
Section: Hsc Injectionmentioning
confidence: 99%
“…Highly publicized trials involving ASCbased therapy for post-myocardial infarction tissue repair have been reported (39)(40)(41). The clinical benefits in patients with myocardial infarction receiving ASC therapies appear convincing and provide a rationale for further research.…”
Section: Diseased Environments and Tissue Regenerationmentioning
confidence: 99%